Facebook tracking pixel
S10.AI
ICD-10-CM · R92.3GeneralSystemic

Breast Density

Understanding breast density, including dense breasts and breast tissue density, is crucial for accurate healthcare documentation and medical coding. This information impacts clinical decision-making related to breast cancer risk assessment and screening recommendations. Learn about the importance of documenting B breast density for appropriate patient care and accurate medical coding compliance.

Also known as
Dense BreastsBreast Tissue Density
Definition

High proportion of fibroglandular tissue in the breast compared to fatty tissue.

Clinical signs

Difficult to see masses on mammograms. May feel firm or lumpy.

Common settings

Mammography screening, breast self-exam, clinical breast exam.

Related Codes

ICD-10 Code Families

Complete code families applicable to R92.3

N60-N64
Diseases of the breast
R92
Abnormal findings on diagnostic imaging of breast
Z87.31
Personal history of breast disease
Code Comparison

When to use each related code

DescriptionWhen to use
High breast density on mammogram.Code when mammogram report indicates heterogeneously dense or extremely dense breast tissue.
Fatty breast tissue seen on mammogram.Code when mammogram report describes almost entirely fatty breast tissue.
Scattered fibroglandular densities in breast.Code when report shows scattered areas of fibroglandular tissue within predominantly fatty breasts.
Documentation

Best-practice checklist

  • ✓Document BIRADS breast density category.
  • ✓Specify density based on mammography.
  • ✓Correlate density with patient age.
  • ✓Note any impact on screening.
  • ✓Record supplemental imaging if done.
Coding & Audit Risks

Common pitfalls to avoid

Unspecified Laterality

Coding breast density requires specifying right, left, or bilateral. Missing laterality impacts reimbursement and quality metrics.

ACR Density Mismatch

Discrepancy between documented ACR density category and coded density may lead to coding errors and compliance issues.

Density Reporting Mandate

Failure to comply with state-specific breast density reporting mandates can result in penalties and patient safety concerns.

Mitigation

Best-practice tips

  • 01Document BIRADS density category using standardized lexicon.
  • 02Supplemental screening (US/MRI) for dense breasts improves detection.
  • 03Patient education on density, risks, and screening options is crucial.
  • 04Regular quality assurance for density assessment & reporting ensures accuracy.
  • 05ICD-10 N62.89, LOINC 76753-3 for accurate coding/documentation.
Clinical Decision Support

Step-by-step checklist

  1. 1

    Confirm dense breast tissue on mammogram report.

  2. 2

    Document BI-RADS density category (A, B, C, or D).

  3. 3

    Assess patient risk factors for breast cancer.

  4. 4

    Consider supplemental screening (e.g., ultrasound, MRI).

  5. 5

    Discuss risks and benefits of supplemental screening with patient.

Documentation Template

Ready-to-paste narrative

Patient presents for breast evaluation.  Breast density assessment performed as part of routine mammographic screening.  Mammographic findings indicate heterogeneously dense breast tissue (ACR BI-RADS category C).  This increased breast density may obscure small masses or other subtle findings on mammography.  Patient counseled regarding the implications of dense breast tissue, including the slightly increased risk of breast cancer and the potential benefit of supplemental screening modalities such as breast ultrasound or MRI.  Risks and benefits of supplemental screening discussed, including false positives, additional cost, and potential anxiety.  Patient's decision regarding supplemental screening documented.  Recommendations for continued routine mammographic screening per established guidelines provided.  Patient education materials on breast density, breast cancer risk factors, and early detection strategies provided.  Follow-up mammogram scheduled in one year.
FAQs

Common questions and answers

How does increased breast density impact the sensitivity and specificity of mammography for breast cancer detection in premenopausal and postmenopausal women, and what supplemental screening strategies should clinicians consider?+

Increased breast density can significantly reduce the sensitivity of mammography, particularly in premenopausal women, as dense tissue can obscure underlying masses. This means that cancers may be missed more often in women with dense breasts. While specificity remains relatively high, the reduced sensitivity presents a challenge. For women with dense breasts, particularly those at higher risk, supplemental screening modalities should be considered. These may include ultrasound, MRI, or molecular breast imaging (MBI). The choice of supplemental screening should be individualized based on the patient's risk factors, age, and personal preferences. Explore how various supplemental screening strategies can improve breast cancer detection rates in women with dense breast tissue.

What are the different BI-RADS breast density categories and how do these categories inform patient management and recommendations for supplemental breast cancer screening?+

The BI-RADS (Breast Imaging Reporting and Data System) classifies breast density into four categories: A (almost entirely fatty), B (scattered fibroglandular densities), C (heterogeneously dense), and D (extremely dense). These categories reflect the proportion of fibroglandular tissue relative to fatty tissue. Categories C and D, representing dense breasts, are associated with a higher risk of breast cancer and decreased sensitivity of mammography. Women categorized as BI-RADS C or D should be informed of their breast density and the associated risks. Clinicians should then discuss the benefits and limitations of supplemental screening options like ultrasound or MRI, tailoring the recommendations to the individual patient’s risk profile and preferences. Consider implementing a standardized breast density notification process within your practice to ensure consistent patient communication. Learn more about risk stratification and personalized screening approaches for women with dense breasts.

Beyond mammograms, what imaging techniques are most effective for detecting breast cancer in patients with extremely dense breasts, and what are the key considerations when choosing between these methods?+

For patients with extremely dense breasts (BI-RADS D), supplemental screening beyond mammography is often recommended. Ultrasound, MRI, and molecular breast imaging (MBI) are potential options. Ultrasound is relatively inexpensive and widely available, but its sensitivity can be operator-dependent. MRI offers high sensitivity, but it is more expensive, time-consuming, and may have a higher false-positive rate. MBI, while less readily available, can be effective in detecting cancers missed by mammography and ultrasound. When choosing between these methods, clinicians should consider factors such as patient age, risk factors, family history, availability of technology, cost, and patient comfort. Each method has its own advantages and limitations, and the optimal approach is individualized. Explore the comparative effectiveness and practical considerations of different advanced imaging techniques for dense breasts to inform your clinical decision-making.

Clinical accuracy: This information is provided for documentation and coding guidance and should not replace professional medical judgment.

Coding standard: ICD-10-CM, current FY guidelines.